Netupitant

Drug Profile

Netupitant

Alternative Names: R 1124; Ro 67-3189/000

Latest Information Update: 19 Sep 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Helsinn; Taiho Pharmaceutical
  • Class Antiemetics; Pyridines; Small molecules
  • Mechanism of Action G protein-coupled receptor modulators; Neurokinin 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chemotherapy-induced nausea and vomiting; Pruritus
  • Discontinued Overactive bladder

Most Recent Events

  • 31 Aug 2017 Phase-II clinical trials in Chemotherapy induced nausea and vomiting (Prevention, In adolescents, In children, In infants, In neonates, Combination therapy) in USA (PO) (NCT03204279)
  • 04 Jul 2017 Helsinn plans a phase II trial for Chemotherapy induced nausea and vomiting (Prevention, In adolescents, In children, In infants, In neonates, Combination therapy) in USA, Russia, Serbia and Ukraine (NCT03204279)
  • 12 Oct 2015 Phase-II clinical trials in Chemotherapy induced nausea and vomiting (Prevention) in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top